Evidence mapPaperPMID 32080754Full record

Observational studyEuropean radiology2020

Post-contrast acute kidney injury in a hospitalized population: short-, mid-, and long-term outcome and risk factors for adverse events.

Wei Cheng, Xi Wu, Qian Liu, Hong-Shen Wang, Ning-Ya Zhang, Ye-Qing Xiao, Ping Yan, Xu-Wei Li, Xiang-Jie Duan, Jing-Cheng Peng and 2 more

Open access · hybridAbstract readObservational Study
In one paragraph

Observational study in European radiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Deliberating a Re(n)al-world Research Setting.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2023
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Wei ChengDepartment of Nephrology, The Second Xiangya Hospital, Hunan Key Laboratory of Kidney Disease and Blood Purification, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, China.
Xi WuDepartment of Nephrology, The Second Xiangya Hospital, Hunan Key Laboratory of Kidney Disease and Blood Purification, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, China.
Qian LiuDepartment of Nephrology, The Second Xiangya Hospital, Hunan Key Laboratory of Kidney Disease and Blood Purification, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, China.
Hong-Shen WangDepartment of Nephrology, The Second Xiangya Hospital, Hunan Key Laboratory of Kidney Disease and Blood Purification, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, China.
Ning-Ya ZhangInformation Center, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Ye-Qing XiaoDepartment of Nephrology, The Second Xiangya Hospital, Hunan Key Laboratory of Kidney Disease and Blood Purification, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, China.
Ping YanDepartment of Nephrology, The Second Xiangya Hospital, Hunan Key Laboratory of Kidney Disease and Blood Purification, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, China.
Xu-Wei LiDepartment of Nephrology, The Second Xiangya Hospital, Hunan Key Laboratory of Kidney Disease and Blood Purification, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, China.
Xiang-Jie DuanDepartment of Nephrology, The Second Xiangya Hospital, Hunan Key Laboratory of Kidney Disease and Blood Purification, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, China.
Jing-Cheng PengDepartment of Nephrology, The Second Xiangya Hospital, Hunan Key Laboratory of Kidney Disease and Blood Purification, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, China.
Song FengInformation Center, The Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Shao-Bin DuanDepartment of Nephrology, The Second Xiangya Hospital, Hunan Key Laboratory of Kidney Disease and Blood Purification, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, China. duansb528@csu.edu.cn.ORCID http://orcid.org/0000-0002-6559-1732
Central South University · CN

Funding

Clinical Medical Technology Innovation Guide Project of Hunan Province 2017SK50117Development and Reform Commission of Hunan Province 2014-658National Natural Science Foundation of China No.81570618, No.81873607Scientific Foundation of Hunan Province, China S2013F1022
6 · The paper itself

Abstract

objectivesTo investigate the prognosis including major adverse kidney events within 30 days (MAKE30) and 90-day and 1-year adverse outcome in hospitalized patients with post-contrast acute kidney injury (PC-AKI) to identify high-risk factors.

methodsThis retrospective observational study included 288 PC-AKI patients selected from 277,898 patients admitted to hospitals from January 2015 to December 2015. PC-AKI was defined according to the 2018 guideline of European Society of Urogenital Radiology. Multivariable Cox regression and logistic regression analyses were used to analyze main outcome and risk factors.

resultsPC-AKI patients with AKI stage ≥ 2 had much higher incidence of MAKE30 than those with AKI stage 1 (RR = 7.027, 95% CI 4.918-10.039). Persistent renal dysfunction, heart failure, central nervous system failure, baseline eGFR < 60 mL/min/1.73 m

conclusionsPC-AKI is not always a transient, benign creatininopathy, but can result in adverse outcome. AKI stage is independently correlated to MAKE30 and persistent renal dysfunction may exaggerate the risk of long-term adverse events. KEY POINTS: • PC-AKI can result in adverse outcome such as persistent renal dysfunction, dialysis, chronic kidney disease (CKD), end-stage renal disease (ESRD), or death. • AKI stage is independently correlated to MAKE30. • Persistent renal dysfunction may exaggerate the risk of long-term adverse events.

Indexed as

MortalityAcute Kidney InjuryAdultAgedContrast MediaFemaleGlomerular Filtration RateHospitalizationHumansKidney Failure, ChronicLogistic ModelsMaleMiddle AgedPrognosisProportional Hazards ModelsRenal DialysisContrast MediaAcute kidney injuryContrast mediaPrognosisRisk factors

Identifiers

PMID32080754
PMCPMC7248019
OpenAlexW3008514842

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.